- 米国企業
- Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.CYCC
時価総額
$2756.1万
PER
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Research and development | 186 | 192 | - | 5 | 5 | 15 | 20 |
| General and administrative | 89 | 89 | - | 5 | 6 | 7 | 7 |
| Total operating expenses | 288 | 287 | - | 10 | 11 | 23 | 28 |
| Operating loss | -16 | -15 | - | -10 | -11 | -23 | -28 |
| Foreign exchange gains (losses) | -0 | 0 | - | 0 | 0 | 0 | 0 |
| Interest income | 14 | 14 | - | 0 | 0 | 0 | 0 |
| Other income, net | - | 0 | - | 0 | 1 | 0 | 1 |
| Total other income, net | 6 | 6 | - | 1 | 1 | 0 | 2 |
| Loss before taxes | -16 | -15 | - | -9 | -10 | -23 | -26 |
| Income tax benefit | -1 | -1 | - | -1 | -1 | -4 | -5 |
| Net loss | -15 | -13 | - | -8 | -8 | -19 | -21 |
| Dividend on convertible exchangeable preferred shares | - | - | - | 0 | 0 | 0 | 0 |
| Beneficial conversion feature of Series B preferred stock | - | - | - | - | 4 | - | - |
| Net loss applicable to common shareholders | - | - | - | -8 | -12 | -19 | -21 |
| Earnings Per Share, Basic | - | - | - | - | - | -2.14 | -1.9 |
| Earnings Per Share, Diluted | - | - | - | - | - | -2.14 | -1.9 |